Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$48.78
-0.4%
$51.22
$47.58
$70.93
$98.87B0.3915.38 million shs4.04 million shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$0.29
+5.0%
$0.36
$0.26
$2.08
$1.74M0.1266,434 shs134,161 shs
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
C$39.13
-0.2%
C$42.52
C$38.58
C$48.27
C$2.20B0.9448,409 shs9,499 shs
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
$86.93
$86.93
$78.50
$103.13
$3.65MN/A450 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-0.28%+1.51%-5.64%-2.47%-30.54%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-2.47%-10.62%-28.12%-27.78%-77.06%
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
+0.43%-2.09%-8.36%-8.51%-2.55%
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.5895 of 5 stars
2.15.03.34.02.41.71.9
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
1.9538 of 5 stars
2.00.01.70.01.61.72.5
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$61.1825.41% Upside
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/A
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
2.00
HoldC$45.2515.64% Upside
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
0.00
N/AN/AN/A

Current Analyst Ratings

Latest BMY, RCH, INM, and WIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/12/2024
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutralC$46.00 ➝ C$45.00
4/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/11/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/6/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $51.00
2/6/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$77.00 ➝ $54.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B2.20$12.38 per share3.94$14.49 per share3.37
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.14M0.42N/AN/A$3.63 per share0.08
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
C$1.79B1.23C$1.12 per share35.00C$16.13 per share2.43
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B$3.8612.646.901.4817.83%50.95%16.67%4/25/2024 (Confirmed)
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.95MN/A0.00N/A-115.76%-54.31%-46.23%5/20/2024 (Estimated)
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
C$111.47MC$1.9819.760.776.24%13.18%8.15%7/4/2024 (Estimated)
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
N/AN/A0.00N/AN/AN/AN/AN/A

Latest BMY, RCH, INM, and WIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.5050N/A+$4.5050N/AN/AN/A  
2/13/2024Q2 2024
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$0.19-$0.19-$0.19N/A$1.24 million
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.404.92%+8.20%62.18%N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
C$0.601.53%N/A30.30%N/A
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
N/AN/AN/AN/AN/A

Latest BMY, RCH, INM, and WIL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2024
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
QuarterlyC$0.151.45%4/24/20244/25/20245/9/2024
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.24
1.43
1.31
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
7.03
6.59
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
23.05
3.62
0.72
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.02 billionOptionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
136.06 million5.97 millionNot Optionable
Richelieu Hardware Ltd. stock logo
RCH
Richelieu Hardware
3,00056.12 millionN/ANot Optionable
Barclays Women in Leadership ETN stock logo
WIL
Barclays Women in Leadership ETN
2,02042,000N/ANot Optionable

BMY, RCH, INM, and WIL Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
InMed Pharmaceuticals logo

InMed Pharmaceuticals

NASDAQ:INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Richelieu Hardware logo

Richelieu Hardware

TSE:RCH
Richelieu Hardware Ltd. manufactures, imports, and distributes specialty hardware and complementary products in Canada and the United States. The company's principal product categories include furniture, glass and building decorative, and functional hardware; lighting systems; finishing and decorating products; ergonomic workstation components; kitchen and closet storage solutions; sliding door systems; decorative and functional panels; high-pressure laminates; railing and balusters; floor protection products; and power tool accessories. It manufactures veneer sheets and edge banding products; various decorative moldings and components for the window and door industry; and custom products. The company serves kitchen and bathroom cabinet, storage and closet, home furnishing, and office furniture manufacturers; door and window manufacturers; residential and commercial woodworkers; and hardware retailers, such as renovation superstores. Richelieu Hardware Ltd. was founded in 1968 and is headquartered in Montreal, Canada.
Barclays Women in Leadership ETN logo

Barclays Women in Leadership ETN

NYSEARCA:WIL